Ann Mullally receives Clinical Investigator Continuation Grant
Ann Mullally, MD, a physician-scientist in the Division of Hematology, was awarded a Clinical Investigator Continuation Grant from the Damon Runyon Cancer Research Foundation for her project, “Peptide Vaccination to Target Mutant Calreticulin in Myeloproliferative Neoplasms (MPN).” The award, which provides $300,000 over two years, will support the development of a clinical trial to target MPN using an anti-cancer vaccine.
Mullally is a translational cancer researcher in the field of myeloid malignancies, a subset of bone marrow cancers. She focuses on MPN—a group of blood cancers arising in the hematopoietic stem cell compartment, in which the bone marrow produces too many red blood cells, white blood cells and/or platelets. Her laboratory studies the genetics, biology and therapy of MPN, using human blood samples and multiple experimental systems, including mouse models.
The Damon Runyon Cancer Research Foundation, founded in 1946, provides young scientists with funding to pursue innovative research. The foundation has achieved global recognition in cancer research by identifying outstanding researchers and physician-scientists. Each award program is competitive, with less than 10 percent of applications funded.